Research & Development
Niagen Bioscience introduces Tru Niagen and Niagen IV at Equinox Hotel New York
14 July 2025 -

Niagen Bioscience, Inc. (NASDAQ: NAGE), a leader in NAD+ science and healthy aging, on Monday announced the debut of its Tru Niagen supplement and Niagen IV therapy at Equinox Hotel New York, marking the company's first hotel collaboration.

Tru Niagen, now available in all guest suites, and Niagen IV, offered through NutriDrip at The Spa by Equinox Hotel New York, aim to enhance cellular energy production and DNA repair. Both products feature Niagen - a patented nicotinamide riboside (NR) - clinically proven to boost NAD+ levels, a key coenzyme that declines with age and stress.

Tru Niagen is supported by over 35 clinical studies and 400 peer-reviewed publications, and is third-party certified, including NSF Certified for Sport status for selected products. Niagen IV, designed as a more tolerable and efficient alternative to standard NAD+ IV therapy, demonstrated a 75% shorter infusion time and a 20% increase in NAD+ levels three hours post-infusion in clinical testing.

Niagen Bioscience, formerly ChromaDex Corp, is expanding its presence in the premium wellness market by aligning with Equinox's luxury, performance-driven hospitality model. Pharmaceutical-grade Niagen IV is available only via prescription at licensed clinics and is compounded by FDA-registered 503B outsourcing facilities.

Login
Username:

Password: